Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients

BACKGROUND: The addition of adjuvant capecitabine to standard chemotherapy of early-stage triple-negative breast cancer (TNBC) patients has improved survival in a few randomised trials and in meta-analyses. However, many patients did not benefit. We evaluated the BRCA1-like DNA copy number signature...

Descripción completa

Detalles Bibliográficos
Autores principales: de Boo, Leonora W., Jóźwiak, Katarzyna, Joensuu, Heikki, Lindman, Henrik, Lauttia, Susanna, Opdam, Mark, van Steenis, Charlaine, Brugman, Wim, Kluin, Roelof J. C., Schouten, Philip C., Kok, Marleen, Nederlof, Petra M., Hauptmann, Michael, Linn, Sabine C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090783/
https://www.ncbi.nlm.nih.gov/pubmed/35124703
http://dx.doi.org/10.1038/s41416-022-01711-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090783/
https://www.ncbi.nlm.nih.gov/pubmed/35124703
http://dx.doi.org/10.1038/s41416-022-01711-y

Ejemplares similares